Cargando...

Targeted therapies for renal cell carcinoma: more gains from using them again

The development of molecularly targeted agents that inhibit pathways critical to the development of renal cell carcinoma has significantly improved outcomes in patients with these cancers. Compelling scientific and phase iii data have made the use of molecularly targeted agents the standard of care...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Gan, H.K., Seruga, B., Knox, J.J.
Formato: Artigo
Idioma:Inglês
Publicado: Multimed Inc. 2009
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC2687802/
https://ncbi.nlm.nih.gov/pubmed/19478898
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!